to 90% of those infected. The government of Liberia says that sample doses of the experimental Ebola drug ZMapp will be sent there to treat doctors who have contracted the deadly virus.
The White House and Food and Drug Administration approved the Liberian request for the drug to be made available to them.
Liberia identified itself as the recipient of the drug after the company that makes ZMapp said earlier that its supply was exhausted after fulfilling the request of a West African country, which it did not name.
The delivery of the ZMapp to Liberia follows a request made on Friday from Liberian President Ellen Johnson Sirleaf to President Barack Obama.
The sample doses will be brought to Liberia by a U.S. government representative this week, the Liberian government said. Why Ebola drug isn't available in Africa. Ebola treatment raises ethical questions Ethicist: Give Africans the Ebola serum.
A World Health Organization panel convened Monday to discuss the ethics of using experimental medicine to fight Ebola in West Africa.
In the current outbreak, the virus is believed to have infected 1,848 people and killed 1,013, according to WHO's latest figures.
There are no proven vaccines or drugs to treat Ebola, but ZMapp was given to two American missionaries infected with the disease early last
week. Both patients had to give consent to receive the drug, knowing it had never been tested in humans before. Their conditions are said to be improving.
ZMapp is also being given to Miguel Pajares, a Spanish priest infected with Ebola while working in Liberia, Spain's Ministry of Heath announced
Saturday. The drug was sent from Geneva, Switzerland, to Madrid, where Pajares is being treated in a special isolation unit at Hospital Carlos
III.
The patients' treatment has raised questions about the use of unproven and unlicensed drugs to treat Ebola and why these three have received the serum when so many others in West Africa also have the virus.
No comments:
Post a Comment